section name header

Pronunciation ⬇

hye-DRAL-a-zeen

Classifications ⬆ ⬇

Therapeutic Classification: antihypertensives

Pharmacologic Classification: vasodilators

Indications ⬆ ⬇

REMS

Unlabeled Use:
  • New York Heart Associated Class III or IV HF with reduced ejection fraction (in combination with isosorbide dinitrate).

Action ⬆ ⬇

  • Direct-acting peripheral arteriolar vasodilator.
Therapeutic effects:
  • Lowering of BP in hypertensive patients and decreased afterload in patients with HF.

Pharmacokinetics ⬆ ⬇

Absorption: Rapidly absorbed following oral administration; well absorbed from IM sites. IV administration results in complete bioavailability.

Distribution: Widely distributed.

Metabolism/Excretion: Mostly metabolized by the GI mucosa and liver by N-acetyltransferase (rate of acetylation is genetically determined [slow acetylators have ↑ hydralazine levels and ↑ risk of toxicity; fast acetylators have ↓ hydralazine levels and ↓ response]).

Half-Life: 2–8 hr.

Time/Action Profile ⬆ ⬇

(antihypertensive effect)

ROUTEONSETPEAKDURATION
PO45 min2 hr2–4 hr
IM10–30 min1 hr3–8 hr
IV5–20 min15–30 min2–6 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: tachycardia, angina, arrhythmias, edema, orthostatic hypotension

Derm: rash

GI: diarrhea, nausea, vomiting

MS: arthralgias, arthritis

Neuro: dizziness, drowsiness, headache, peripheral neuropathy

Misc: drug-induced lupus syndrome

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Apresoline

Code ⬆

NDC Code